Severity and Risk of Death Due to COVID 19

Author:

Shaymaa Hasan Abbas ,Rasha Saadi Abbas ,Lubab Tarek Nafea

Abstract

A novel SARS-CoV2 virus appeared since December 2019 and triggering the Corona virus disease (2019-nCoV or COVID-19). Usually the symptoms begin as mild, with only fever, cough, and occasional dyspnea. The severe symptoms such as   pneumonitis, and acute respiratory distress syndrome (ARDS), may occur 5-8 days into COVID-19 illness in a minority of patients. Method:  for this narrative review, more than 25 related scientific articles and reports about COVID- 19 were used from different databases (e.g., PubMed, Google Scholar, and Web of Science) using keywords such as SARS-CoV2, COVID-19, Mortality, and CO-morbidities. Results The results of this review reported that aged people are more vulnerable to severe pattern of COVID-19 disease than people younger than 50 years; probably because of health issues and comorbidities in that population group. Male more than female affected by COVID-19. On the other hand, children might be less probable to infected or might show mild symptoms if infected. The small percentage of current smokers infected with COVID-19 compared with the actual percentage of smokers (50·5%) in China are unlikely to be related with the incidence, severity, or mortality rate of COVID-19. The poorer clinical outcome in COVID-19  infected patients may have related to the presence and number of co morbidities especially hypertension, diabetes and cardiovascular diseases.  The direct SARS-COV2 infection of liver cells might be the cause of liver damage but might be related to other reasons such as systemic inflammation and drug toxicity. The data   suggested that liver damage is more predominant in severe cases especially with pre-existing liver diseases. patients with cancer might be more prone to COVID 19 due to their immunocompromised status but whether or not they have high risk of poor prognoses and sever event not fully established.

Publisher

Al Mustansiriyah University - College of Pharmacy

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3